How did you decide to participate in the Biomapas Academy?
When I used to walk past a pharmacy every day, I could never stop dreaming about being able to help people and develop innovative pharmaceuticals. So while studying biomedical sciences, I became interested in the drug development paths, which led me to medicinal chemistry. And one day at the university, I saw a poster about the Biomapas Academy, which could help me understand what, how, where, and when happens to pharmaceutical products during the whole journey to reach us, so I signed up for it without hesitation. Even though I am usually not a lucky person, I was selected to be one of the participants, which surprised me!
How was your experience regarding the Academy?
During the few months, I deepened my existing knowledge of drug development stages and expanded it to learn more about drug regulation and pharmacovigilance. After graduating from the Academy, I got the opportunity to try out regulatory affairs as part of Biomapas – I completed a summer internship in the Regulatory Affairs department.
How do you feel after graduating from the Academy?
I will never forget this practice in my life, not only because it fulfilled what I was looking for, but it let me realize that I want to return to this company after my graduation and put my accumulated knowledge to use. Thanks again to all Biomapas staff for their insights and advice, and I hope to see you soon.
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
MENA PV Landscape – Key Updates & Inspection Trends
Timely insights on the evolving Pharmacovigilance landscape in the MENA region.
Navigating Pharmacovigilance Requirements in LATAM
Insights into the evolving Pharmacovigilance landscape across the LATAM region.
Centralized Pharmacovigilance: Ensuring Compliance and Efficiency Across Global Markets
This article explores the benefits of centralized pharmacovigilance outsourcing and the single-provider model.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
Discover insights on diversity in clinical trials, regulatory compliance to inclusion, the European approach, and trial design innovations.
Biomapas Welcomes David Passov as Chief Executive Officer
Press Release Biomapas Welcomes David Passov as Chief Executive OfficerWe are pleased to announce the appointment of David Passov, MBA, as our new Chief Executive Officer, effective 21st February 2025. David Passov brings extensive leadership experience in life...
How functional service provision (FSP) helps biotech companies streamline clinical trial operations
In recent years, biotech companies face pressure to optimize clinical trial operations while managing costs, ensuring regulatory compliance, and maintaining flexibility. This is where Functional Service Provision (FSP) comes in. FSP offeres a scalable, flexible...
Functional Service Provision As Smarter Approach to Clinical Trial Execution
For biotech and pharmaceutical companies, the challenge isn’t just innovation but execution too. Functional Service Provision (FSP) enables organizations to optimize clinical trials without the bottlenecks of traditional outsourcing. As competition intensifies and...
Pharmacovigilance Auditing: Understanding the Process and Maximizing Its Benefits
Discover how pharmacovigilance audits go beyond compliance to uncover hidden risks, drive improvement, and ensure every patient gets the safest treatment possible.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
In light of recent developments, we must recognise that diversity in clinical trials is not just a buzzword anymore, it is a key priority. Yet, with varying perspectives from regulatory agencies worldwide, and an industry still unaligned on the best approaches, there...
All you need to know about the FDA’s Draft Guidance on Diversity Action Plans
The U.S. Food and Drug Administration’s (FDA) draft guidance on Diversity Action Plans (DAPs) is a significant step towards addressing the underrepresentation of diverse populations in clinical research. Released in June 2024, this guidance aligns with broader efforts...
